目的：探讨羟苯磺酸钙分散片联合明目地黄丸治疗非增殖期糖尿病视网膜病变(NPDR)患者的临床疗效、以及对视网膜新生血管相关因子及血脂水平的影响。

方法：选择2017-01/2018-03在我院进行治疗的100例NPDR患者作为研究对象，将其随机分为对照组(50例，采用羟苯磺酸钙分散片进行治疗)以及观察组(50例，在对照组基础上加用明目地黄丸进行治疗)。比较两组治疗前后临床评价指标、视网膜新生血管相关因子及血脂水平。

结果： 治疗前，两组患者临床评价指标、视网膜新生血管相关因子及血脂水平无差异(P>0.05)。治疗2个疗程后，两组患者视野灰度值、血管瘤体积、黄斑厚度、出血斑面积、血管内皮生长因子、胰岛素样生长因子-1(IGF-1)、组织因子(TF)、总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)水平均较治疗前显著降低(P<0.05)； 视力、色素上皮衍生因子及高密度脂蛋白胆固醇(HDL-C)水平则较治疗前显著升高(P<0.05)； 且观察组视野灰度值、血管瘤体积、黄斑厚度、出血斑面积、VEGF、IGF-1、TF、TC、TG及LDL-C水平较对照组降低明显(P<0.05)，视力、PEDF及HDL-C水平较对照组升高明显(P<0.05)。

结论：羟苯磺酸钙分散片联合明目地黄丸治疗能显著改善患者临床评价指标、抑制血管新生及改善血脂水平。

METHODS: Totally 100 cases of non-proliferative diabetic retinopathy(NPDR)patients treated in our hospital from January 2017 to March 2018 were selected as the study subjects. They were randomly divided into observation group(n=50)and control group(n=50). The control group was treated with calcium oxybenzosulfonate dispersible tablets, the observation group was treated with Mingmu Dihuang pills on the basis of the control group. The clinical evaluation indexes, retinal angiogenic factors and blood lipid levels of the two groups before and after treatment were observed and compared.

RESULTS: Before treatment, there were no significant differences in clinical evaluation indexes, retinal angiogenic factor and blood lipid levels between the two groups(P>0.05).After treatment, the visual field gray value, hemangioma volume, macular thickness, hemorrhage area, vascular endothelial growth factor(VEGF), insulin-like growth factor-1(IGF-1), tissue factor(TF), total cholesterol(TC), triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)levels in the two groups were significantly lower than before treatment(P<0.05). Visual acuity, pigment epithelial-derived factor(PEDF)and high-density lipoprotein cholesterol(HDL-C)were significantly higher than before treatment(P<0.05). The levels of VEGF, IGF-1, TF, TC, TG and LDL-C in the observation group were significantly lower than those in the control group(P<0.05), and the levels of visual acuity, PEDF and HDL-C were significantly higher than those in the control group(P<0.05).

CONCLUSION: Calcium oxybenzosulfonate dispersible tablets combined with Mingmu Dihuang pills can significantly improve the clinical evaluation index, inhibit angiogenesis and improve the level of blood lipid.